



19th European Society for Biomedical Research on Alcoholism Conference

September 1st - September 3rd 2023
Medical University Graz



PROGRAM

19th European Society for Biomedical Research on Alcoholism Conference



Scientific Committee

Dr. Daniel König-Castillo
Generale Hospital (AKH) Vienna

Dr. Francesca Sarocchi
Medical University Graz

Dr. Stephan Sygulla
Medical University Graz

Univ.-Prof. Dr. Karoline Lackner
Medical University Graz

Dr. Verena Stangl
Medical University Graz

Assoz. Prof. Priv.-Doz. Dr. Martin Wagner
Medical University Graz

Prof. Mickael Naassila, PhD
Université de Picardie Jules Verne

Univ.-Prof. Dr. Rudolf Stauber
Medical University Graz


Priv.-Doz. Dr. Jolana Wagner-Skacel
Medical University Graz

Univ.-Prof. Dr. Otto Lesch
Medical University Graz

Organization

conventa e.U.
Villefortgasse 22, A-8010 Graz
+43 316 316254
office@conventa.at

Sponsors



FOREWORD


Dear colleagues,

On behalf of the Local Organizing Committee I would like to extend a warm welcome to you to Graz, and the 19th Conference of the European Society for Biomedical Research. It's a great honour for the Medical University and the City of Graz to host this congress dedicated to research into alcohol-related diseases, which albeit their frequency and substantial adverse impact on public health are underrepresented issues in society, politics, clinical management as well as research. The focus of this years programme was to provide a broader spectrum of alcohol-related topics including epidemiology, genetics, metabolism, immunology, pathology, and clinical aspects. Our programme features exciting plenary sessions, keynote as well as the Nordmann and Helmut Seitz Award lectures and symposia delivered by renowned experts. It's also important to acknowledge the valuable contributions of young investigators, speakers of the free oral presentations, and poster presenters.

Graz is a lovely, vibrant city with a rich history, being a UNESCO World Heritage Site, European Culture Capital 2003, and a Unesco City of Design. I'm sure attendees will have a great opportunity exploring the local attractions, including the historical old city and gather some culinary experiences since Graz is also Austrias first Capital of Culinary Delights!

We hope the conference proves to be a fruitful platform for knowledge sharing, networking, and advancing research in the field of alcohol-related diseases.

Univ.-Prof. Dr. Carolin Lackner
Congress President



FRIDAY, SEPTEMBER 1ST

AULA

Opening ceremony

Epidemiology of alcohol-related organ disease in Europe

Plenary Session 1

HÖRSAAL 3 LECTURE HALL 3

HÖRSAAL 4 LECTURE HALL 4

09:00 - 09:30	Opening ceremony		
09:30 - 10:15	Epidemiology of alcohol-related organ disease in Europe		
	Plenary Session 1		
10:15 - 10:30	COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)		
10:30 - 11:50	Alcohol-related burden of disease: epidemiologic, economic and social implications (1)	Alcohol-related liver injury: role of dysregulated lipid metabolism	Management of alcohol-use disorder (1)
	Session 1	Session 6	Session 11
11:50 - 12:10	COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)		
12:10 - 13:30	Alcohol-related burden of disease: epidemiologic, economic and social implications (2)	Gut-liver axis (1)	Management of alcohol-use disorder (2)
	Session 2	Session 7	Session 12
13:30 - 14:30	LUNCH		
14:30 - 15:50	Social cognition and problematic alcohol use	Gut-liver axis (2)	Management of alcohol-use disorder (3)
	Session 3	Session 8	Session 13
15:50 - 16:10	COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)		
16:10 - 17:30	Effects of binge-drinking in adolescence	Gut-liver-brain axis (1)	The role of the nucleus of the amygdala (CeA) for regulation of behavioural dysfunctions related to alcohol exposure
	Session 4	Session 9	Session 14
17:30 - 17:50	COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)		
17:50 - 19:10	Genetic implications in alcohol-related organ damage	Mechanisms of cholestasis in alcohol-related liver disease 17:50 - 18:30	Young investigators at the Medical University of Graz 17:50 - 18:50
	Session 5	Session 10 - Key note lecture 1	Session 15
19:20 - 23:00	Social program: Bus transfer to the barbecue evening at the mountain hut „Latschen-Hütte“, Teichalm		

SATURDAY, SEPTEMBER 2ND

AULA

HÖRSAAL 3 LECTURE HALL 3

HÖRSAAL 4 LECTURE HALL 4

08:00 - 08:45	Mallory-Denk bodies and hepatocellular ballooning Plenary Session 2		
08:50 - 09:40	Helmut Seitz Award Lecture		
09:40 - 10:00		COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)	
10:00 - 11:20	Alcohol and carcinogenesis Session 16	Histology of alcohol-related liver disease Session 22 Digital assisted image analysis Key note lecture 2	Joint ESBRA-JMSAAS meeting Session 27
11:20 - 11:40		COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)	
11:40 - 13:00	Alcohol-related multisystemic organ injury Session 17	Noninvasive assessment of liver fibrosis in alcohol related liver disease Session 23	Free oral presentations (1) 11:40 - 13:20 Session 28
13:00 - 14:00		LUNCH	
14:00 - 15:30	Young investigators at the Medical University of Vienna Session 18	Management of alcohol-related liver disease: The patients perspective Session 24	Gut-liver-brain axis (2) Session 29
15:30 - 15:50		COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)	
15:50 - 17:10	Alcohol-induced progression to end-stage liver disease Session 19	Management of alcohol-related liver disease (1) Session 25	Albumin & ALD Session 30
17:10 - 17:30		COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)	
17:30 - 18:50	Alcohol and bone injury Session 20 - key note lecture 3 Awardees of ESBRA travel fellowship Session 21	Management of alcohol-related liver disease (2) Session 26	Iron and alcohol-related liver disease Session 31

SUNDAY, SEPTEMBER 3RD

AULA

08:00 - 08:45

A novel treatment strategy for alcohol use disorder with phosphodiesterase 7 (PDE7) inhibitors

Plenary Session 3

08:50 - 09:45

Nordmann Award Lecture

09:45 - 10:00

COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)

10:00 - 10:40

General assembly

10:40 - 12:00

Alcohol-related inflammation and the brain

Session 32

Alcohol and heart disease

10:40 - 11:40

Session 34

Free oral presentation (2)

Session 36

12:00 - 12:20

COFFEE BREAK & POSTER VIEWING (Lecture Hall 5)

12:20 - 13:40

GABA_B receptor and alcohol use disorder

Session 33

Korsakow´s syndrome update

Session 35

Intensive care

Session 37

14:00 - 14:30

Closing remarks & fare well

HÖRSAAL 3 LECTURE HALL 3

HÖRSAAL 4 LECTURE HALL 4

FRIDAY, SEPTEMBER 1ST

08:00 - 09:00

Registration

09:00 - 09:30 AULA

Opening Ceremony

09:30 - 10:15 AULA

Plenary session 1: Epidemiology of alcohol-related organ disease in Europe

Chairs: *R. Stauber, AUT; C. Lackner, AUT*

H. Cortez-Pinto, PRT

10:30 - 11:50 AULA

Alcohol-related burden of disease: epidemiologic, economic and social implications (1)

Session 1: Stigma in people with alcohol use disorder (AUD) or alcohol-related liver disease (ARLD)

Chairs: *A. Dhanda, UK; P. Carrieri, FRA*

What's in a name? Can novel liver disease nomenclature reduce alcohol-related stigma and harms?
P. Mathurin, FRA

How to reduce stigma: a clinical and policy perspective
P. Carrieri, FRA

What can a hepatologist do to tackle stigma?
A. Dhanda, UK

Perspectives on stigma from people with lived experience of AUD and ARLD
L. Manning, UK



FRIDAY, SEPTEMBER 1ST

10:30 - 11:50 HÖRSAAL 3 (LECTURE HALL 3)

Alcohol-related liver injury: role of dysregulated lipid metabolism

Session 6: New insights into mechanisms of dysregulated lipid metabolism and its role in the progression of alcohol-associated liver disease

Chairs: C. Casey, USA; M. McNiven, USA

An ethanol-based disruption of the ubiquitin-proteasome transporter protein VCP induces hepatocyte steatosis by an accumulation of the LD surface enzyme HSD17B13

M. McNiven, USA

Role of long noncoding RNA H19 in regulation of lipid metabolism in alcohol associated liver disease

L. Gobejishvili, USA

Host-derived 5S rRNA pseudogene transcripts are associated with inflammatory responses in alcohol-associated hepatitis

L. Nagy, USA

Is hepatic steatosis really a mandatory disease stage or just a bystander in alcohol-related liver disease?

S. Müller, GER

10:30 - 11:50 HÖRSAAL 4 (LECTURE HALL 4)

Management of alcohol-use disorder (1)

Session 11: Treatment of alcohol use disorder: safety and efficacy of precision medicine in selected patients

Chairs: J. Chick, UK; G. Addolorato, IT

Why we need new anti-craving medications

H. Alho, FIN

Subgroups of alcohol dependence and their special treatment

O. Lesch, AUT

New approaches in the treatment of alcohol dependence (virtual)

B. Johnson, USA

Treatment of AUD in patients with different severity of liver disease

G. Addolorato, IT

FRIDAY, SEPTEMBER 1ST

12:10 - 13:30 AULA

Alcohol-related burden of disease: epidemiologic, economic and social implications (2)

Session 2: New insights regarding individual and environmental factors associated with changes in alcohol use: population-based epidemiologic approaches

Chairs: *G. Airagnes, FRA*

Bilateral relationships between cannabis and alcohol go mainly from cannabis to alcohol

J. Matta, FRA

Factors associated with self-reported changes in alcohol use among young adults during the COVID-19 pandemic: a comparative analysis between Canada and France

P.-J. Coulaud, CAN

Changes in alcohol use during the COVID-19 pandemic in health students: the roles of other substance use and literacy in health

G. Airagnes, FRA

Atypical working hours and changes in alcohol use among workers from various sociodemographic backgrounds

N. Hamieh, FRA

12:10 - 13:30 HÖRSAAL 3 (LECTURE HALL 3)

Gut-liver axis (1)

Session 7: Gut-liver interaction in alcohol-associated organ damage

Chairs: *K. Kharbanda, USA; C. Casey, USA*

Ethanol-induced alterations in the gut-liver axis promotes alcohol-associated liver disease: protection by betaine treatment

K. Kharbanda, USA

Gut barrier impairment is key disease driver in ALD

S. Chokshi, UK

Calcium channels in the intestinal epithelium play a crucial role in alcohol induced tissue injury at the gut-liver and gut-brain axis

R. Rao, USA

Role of microbiota dysbiosis and leaky gut in alcohol-induced organ damage

A. Keshavarzian, USA

FRIDAY, SEPTEMBER 1ST

12:10 - 13:30 HÖRSAAL 4 (LECTURE HALL 4)
Management of alcohol-use disorder (2)

Session 12: How to improve cognitive abilities to favor treatment outcome? New perspective and innovative tools

Chairs: A. L. Pitel, FRA; P. Maurage, BEL

Cognitive training and remediation for substance use disorders

A. Verdejo-Garcia, AUS

Mindfulness-based relapse prevention for drinking reductions

K. Witkiewitz, USA

Preventing relapse in alcohol disorder using sensori-motor EEG-neurofeedback training: an event-related potentials study

C. Dousset, BEL

The use of virtual reality and 360° immersive videos to study and treat alcohol abuse and addiction

E. Quertemont, BEL

13:30 - 14:30 INSTITUTE OF PATHOLOGY, LIBRARY

ESBRA ECI committee meeting

13:30 - 14:30 INSTITUTE OF PATHOLOGY, MEETING ROOM

ESBRA Board meeting

14:30 - 15:50 AULA

Social cognition and problematic alcohol use

Session 3: Recent advances in the study of social cognition and problematic alcohol use

Chairs: A. Pabst, P. Maurage, BEL

Acute effects of alcohol on empathy in heavy drinking young adults

L. Kumar, USA

Longitudinal relationships between empathy and alcohol-related outcomes in heavy drinkers

E. Claus, USA

Alcohol use disorder displays trait-related reductions in prosocial decision making

S. Jangard, SWE

Altered attention to facial features in patients with severe alcohol use disorder

A. Pabst, BEL

FRIDAY, SEPTEMBER 1ST

14:30 - 15:50 HÖRSAAL 3 (LECTURE HALL 3)

Gut-liver axis (2)

Session 8: Role of intestinal microbiota, barrier dysfunction and autophagy for onset, progression and treatment of ALD

Chairs: *I. Bergheim, AUT; K. Ikejima, JPN*

Gut-liver axis in ALD development: more than just the microbiome and dysbiosis

P. Stärkel, BEL

Modulation of the intestinal NO homeostasis as trigger of intestinal barrier dysfunction in the development of alcohol-related disease

A. Baumann, AUT

Pharmaco-nutritional approaches to metabolic dysfunction-associated fatty liver disease

A. Uchiyama, JPN

The role of autophagy and nuclear proteins in the pathophysiology of steatohepatitis

S. Yamashina, JPN

14:30 - 15:50 HÖRSAAL 4 (LECTURE HALL 4)

Management of alcohol-use disorder (3)

Session 13: Sodium oxybate for the treatment of alcohol dependence: results from an international clinical development and research project and perspectives

Chairs: *O. Lesch, AUT; W. van den Brink, NL*

Sodium oxybate for the treatment of alcohol use disorder: well-tolerated over 30+ years of clinical use

H. Walter, AUT

Sodium oxybate for the treatment of alcohol withdrawal syndrome: results from two phase 3 randomized, double-blind, active-controlled trials

O. Lesch, AUT

Sodium oxybate for the maintenance of abstinence in alcohol dependent patients: results from a phase 3 international, multicenter, randomized, double-blind, placebo-controlled trial

W. van den Brink, NL

The effect of population severity and treatment duration on sodium oxybate efficacy in the maintenance of abstinence in alcohol dependent patients

J. Guiraud, NL

FRIDAY, SEPTEMBER 1ST

16:10 - 17:30 AULA

Effects of binge-drinking in adolescence

Session 4: Binge drinking during adolescence: latest developments

Chairs: *P. Maurage, BEL; L. Hipolito, ESP*

Stress, cognition and alcohol use during adolescence: does acute stress play a role in cognitive impairments associated with risky alcohol consumption?

S. Suarez, BEL

Microbiome and cognitive alterations in young binge drinkers

C. Carbia, IR & BEL

Alcohol-specific memory inhibition training in binge drinkers: a doubleblind randomized controlled trial examining alcohol use and craving levels

N. Almeida-Antunes, PRT

Neurofunctional precursors to binge drinking in adolescence: longitudinal findings on electrophysiological functional connectivity profiles and executive control abilities

L. F. Antón Toro, ESP

16:10 - 17:30 HÖRSAAL 3 (LECTURE HALL 3)

Gut-liver-brain axis (1)

Session 9: Metabolomics as a new tool to investigate the gut-liver-brain axis and the treatment response in AUD

Chairs: *P. de Timary, BEL; C. Carbia, BEL*

Untargeted and target lipidomics reveal sphingomyelins as a driver of small gut T cell apoptosis in alcohol use disorder (AUD) patients

P. Stärkel, BEL

Comparison of metabolite profiles of persons with progressive ALD to persons with non-progressive ALD and healthy controls identify possible metabolic processes associated with progressive ALD

E. Puhakka, FIN

Gut microbiota-derived metabolites and their potential neuroactive properties, as a way to investigate the gut-brain axis in AUD patients

S. Leclercq, BEL

Baseline metabolite profile could be useful for personalized medicine in AUD patients

O. Kärkkäinen, FIN

FRIDAY, SEPTEMBER 1ST

16:10 - 17:30 HÖRSAAL 4 (LECTURE HALL 4)

The role of the nucleus of the amygdala (CeA) for regulation of behavioural dysfunctions related to alcohol exposure

Session 14: Central nucleus of the amygdala and alcohol use disorder: Perspectives from studies in mice to humans

Chairs: *M. Roberto, USA; K. Radwanska, POL*

Innate immune-related mechanisms in AUD: a view from the tipsy amygdala synapses

M. Roberto, USA

A central amygdala molecular mechanism in punishment-resistant alcohol selfadministration

E. Domi, SWE & IT

Role of the epigenetic enzyme EZH2 in compulsive alcohol intake

E. Barbier, SWE

Arc controls alcohol relapse by a central amygdala mechanism

K. Radwanska, POL

17:50 - 19:10 AULA

Genetic implications in alcohol-related organ damage

Session 5: Genetics of alcohol-related liver disease: risk factors, risk prediction and potential therapeutic approaches

Chairs: *D. Seth, AUS; M. Morgan, UK*

Genetic and environmental risk factors for AUD and ALD

M. Morgan, UK

Genetic and lipid biology in liver disease

D. Seth, AUS

Polygenic risk scores for risk stratification in ALD (virtual)

L. Schwantes-An, USA

Hot topics and emerging themes: round up

D. Seth, AUS; M. Morgan, UK

FRIDAY, SEPTEMBER 1ST

17:50 - 18:30 HÖRSAAL 3 (LECTURE HALL 3)
Mechanisms of cholestasis in alcohol-related liver disease

Session 10: Key note lecture 1:
Mechanisms of cholestasis in alcohol-related liver disease

Chairs: *R. Stauber, AUT; H. Denk, AUT;*
P. Fickert, AUT

17:50 - 18:50 HÖRSAAL 4 (LECTURE HALL 4)
Young investigators at the Medical University of Graz

Session 15: The role of nuclear receptors and fibroblast growth factors in alcohol-related organ disease

Chairs: *J. Wagner-Skacel, M. Wagner, AUT*

FGF21 and personality functioning: a potential marker of abstinence

J. Wagner-Skacel, AUT

Neuropeptid Y and FGF21 in the gut-liver-brain axis

A. Farzi, AUT

FGF21 supresses alcohol consumption through an amygdalo-striatal circuit

A. Horvath, AUT

19:20 - 23:00

Social program: Bus transfer to the barbecue evening at the mountain hut „Latschen-Hütte“, Teichalm

SATURDAY, SEPTEMBER 2ND

08:00 - 8:45 AULA

Plenary session 2: Mallory-Denk bodies and hepatocellular ballooning. Historical perspectives, causes and consequences of protein misfolding in steatohepatitis

Chair: C. Lackner, AUT

H. Denk, AUT

8:50 - 9:40 AULA

Helmut Seitz Award Lecture & Ceremony: positive allosteric modulators of the GABAB: a new class of ligands with therapeutic potential for alcohol use disorder

Chair: M. Naassila, FRA

G. Colombo, IT

10:00 - 11:20 AULA

Alcohol and carcinogenesis

Session 16: New paradigms in alcohol-associated carcinogenesis and tumor progression

Chair: A. Petrosyan, USA

P53-destabilizing protein recruits NOTCH to mitochondria to reprogram liver tumor-initiating stem-like cells induced by alcohol

K. Machida, USA

Adolescent- and adult-initiated alcohol exposure in mice differentially promote tumorigenesis and metastasis of breast cancer

J. Luo, USA

The role of alcohol-induced golgi disorganization and ER stress in the metastatic potential of prostate tumor

A. Petrosyan, USA

Mechanisms of chronic alcohol exposure induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal

A. Courtois, FRA

10:00 - 11:20 HÖRSAAL 3 (LECTURE HALL 3)

Histology of alcohol-related liver disease

Session 22: Histological features of alcohol-related liver disease and implications for clinical management

Chairs: D. Tiniakos, GRC; C. Lackner, AUT

Histological features of alcohol-related liver disease and grading and staging

S. Sakellariou, GRC

High Resolution and single-fiber Digital Pathology and AI, from Liver Organoids to HCC and outcomes-morphological features of steatotic liver disease

M. Petitjean, USA

Key note lecture 2: Digital assisted image analysis - emerging morphologic methods of tissue analysis. Potential impact and pitfalls

Chairs: H. Denk, AUT; K. Zatloukal, AUT

D. Tiniakos, GRC

SATURDAY, SEPTEMBER 2ND

10:00 - 11:20 HÖRSAAL 4 (LECTURE HALL 4)

Joint ESBRA-JMSAAS meeting

Session 27: Alcohol-related diseases: from brain to liver function

Chairs: *S. Müller, GER; K. Ikejima, JPN*

Survey of the relationship between alcohol-related cognitive dysfunction and cerebral blood flow

T. Shirasaka, JPN

International cooperation in treatment of substance use disorders: The INTREPRET study in the Philippines

T. Harada, JPN

Alcohol-related immune modulation during acute-on-chronic liver failure is associated with disease severity and progression

A. Riva, UK

Targeted reprogramming of inflammatory macrophages using prednisolone-loaded nanoliposomes attenuates alcohol-associated liver diseases

R. Bansal, NL

11:40 - 13:00 AULA

Alcohol-related multisystemic organ injury

Session 17: The multisystemic impact of unhealthy alcohol use; immune, metabolic, and neuropathological consequences

Chair: *P. Molina, USA*

Alcohol promotes Alzheimer's disease progression through neuroinflammation and metabolic dysfunction

L. Coleman, USA

Contribution of alcohol associated metabolic instability to aging comorbidities

P. Molina, USA

Alcohol impact on gut-brain axis in Parkinson

A. Keshavarzian, USA

Alcohol-induced suppression of hepatocyte innate immunity; disrupts parenchymal and non-parenchymal cell crosstalk and exacerbates viral pathogenesis

N. Osna, USA

SATURDAY, SEPTEMBER 2ND

11:40 - 13:00 HÖRSAAL 3 (LECTURE HALL 3)
Noninvasive assessment of liver fibrosis in alcohol related liver disease

Session 23: Noninvasive assessment of liver fibrosis in alcohol related liver disease

Chairs: *I. Sporea, ROU; S. Müller, GER*

Biological tests in ALD assessment

A. Popescu, ROU

The place of elastography in ALD

I. Sporea, ROU

How can we screen the ALD patients for liver fibrosis?

S. Müller, GER

Non-invasive assessment of portal hypertension in patients with ALD

I. Grgurevic, HRV

11:40 - 13:20 HÖRSAAL 4 (LECTURE HALL 4)
Session 28: Free oral presentation (1)

Chairs: *J. Wagner-Skacel, AUT; K. Zatloukal, AUT*

Cannabidiol (CBD) to reduce alcohol consumption: a qualitative approach

C. Casanova, FRA

The CNI model of moral decision making in severe alcohol use disorder

M. Gautier, BEL

Physiological manifestations of craving in binge-drinking and severe alcohol use disorder: a phenomenological approach

P. Billaux, BEL

The effects of N-acetylcysteine on intrinsic connectivity and neural alcohol cue reactivity in individuals with alcohol use disorder

W. Logge, AUS

A new statistical model for binge drinking pattern classification in college students populations

J. Andre, Amiens, FRA

The Role of interoception in addictive disorders: a systematic review and a new framework

O. Desmedt, CH

Comparisons of structural brain alterations in patients with alcohol and cocaine use disorders

A. Maillard, FRA

.....

SATURDAY, SEPTEMBER 2ND

Effects of proximal, contextual, and social alcohol cues on craving in an immersive virtual environment

M. Heck, BEL

A prospective comparison of bipolar I and II subjects with and without comorbid alcohol dependence from the COGA dataset

U. Preuss, GER

Psychedelics in AUD: From mechanisms to targeted intervention

M. Meinhardt, GER

**13:00 - 14:00 INSTITUTE OF PATHOLOGY, LIBRARY
ESBRA Early-career Investigators
Committee: launch of mentorship program**

14:00 - 15:30 AULA

**Young investigators at the Medical
University of Vienna**

Session 18: Early career investigators symposium

Chairs: D. König-Castillo, A. Kaltenböck; AUT

Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis

B. S. Hofer, AUT

Hepatic plgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice

D. Rajcic, AUT

Sex disparities in outcome of patients with alcohol-related liver cirrhosis within the Eurotransplant network - a competing analysis

S. Weber, AUT

Dissociative symptoms of patients with alcohol use disorder undergoing alcohol withdrawal treatment - a qualitative study

A. Kaltenböck, AUT

14:00 - 15:30 HÖRSAAL 3 (LECTURE HALL 3)

Management of alcohol-related liver disease: The patients perspective

Session 24: Patient centered management of compensated alcohol-related liver disease: current status and unmet needs

Chairs: H. Stefanescu, ROU

What does a patient with ARLD expect from the healthcare system?

ELPA representative / recording of H. Stefanescu (ROU) interviewing a patient

Individual and societal determinants of ARLD screening (virtual)

M. Ventura Cots, ESP

Secondary prevention of ARLD in the Baveno VII era (virtual)

B. Procopet, ROU

Integrated outpatient care systems for ARLD patients (virtual)

R. Fennel, UK

SATURDAY, SEPTEMBER 2ND

14:00 - 15:30 HÖRSAAL 4 (LECTURE HALL 4)

Gut-liver-brain axis (2)

Session 29: Brain dysfunction in alcohol-related liver disease

Chairs: S. Chokshi, A. Hadjihambi, UK

No safe level of alcohol consumption for brain health

A. Topiwala, UK

Abnormal oxygen homeostasis as a major driver of alcohol and liver disease induced brain dysfunction

A. Hadjihambi, UK

Hepatic encephalopathy: is it truly reversible following liver transplantation?

N. Weiss, UK

Circulating novel biomarkers of neuronal injury have potential for the stratification and risk profiling of hepatic encephalopathy in cirrhosis

V. Patel, UK

15:50 - 17:10 AULA

Alcohol-induced progression to end-stage liver disease

Session 19: Alcohol-induced progression to end-stage liver disease

Chairs: N. Osna, K. Kharbanda, USA

Novel translational aspects of hepatic iron accumulation in heavy drinkers

S. Müller, GER

The role of H3K4 methylation in alcohol-associated liver disease resolution

I. Tikhanovich, USA

Pro-fibrotic activation of hepatic stellate cells by engulfment of hepatocytederived apoptotic bodies generated in the context of HIV infection in response to ethanol metabolites

N. Osna, USA

Overview on clinically relevant ex-vivo models of ALD including precision-cut liver slices and liver organoids

S. Chokshi, UK

SATURDAY, SEPTEMBER 2ND

15:50 - 17:10 HÖRSAAL 3 (LECTURE HALL 3)

Management of alcohol-related liver disease (1)

Session 25: Management of alcohol-related liver disease - overview

Chairs: S. G. Rodrigues, CH; C. Becchetti, IT

Optimizing the management of alcohol use disorder in patients with liver disease (virtual)

P. Pfeifer, CH

How to best identify and stage liver fibrosis and risk of liver-related events? (virtual)

M. Thiele, DK

Advanced alcohol-related liver disease – managing the failing liver

S. G. Rodrigues, CH

Liver transplantation in the ArLD: challenging old paradigms and shedding light on novel aspects

C. Becchetti, IT

15:50 - 17:10 HÖRSAAL 4 (LECTURE HALL 4)

Albumin & ALD

Session 30: Role of albumin in alcohol-related liver disease

Chairs: P. Caraceni, IT; R. Stauber, AUT

Structural and functional properties of human serum albumin

K. Oettl, AUT

The concept of effective albumin concentration in chronic liver failure

P. Caraceni, IT

Molecular adsorbents recirculating system (MARS) in severe alcohol-related hepatitis

M. Kukla, POL

Hepalbin®-based extracorporeal liver support: first results

J. Stange, GER

SATURDAY, SEPTEMBER 2ND

17:30 - 17:50 AULA

Alcohol and bone injury

Session 20: Key-note lecture 3: Overview on compartment and cell-specific alcohol effects on bone involving oxidative-stress dependent and independent mechanisms and acetate

Chairs: M. Naassila, FRA; S. Chokshi, UK
M. Ronis, USA

17:50 - 18:50 AULA

Session 21: Awardees of ESBRA travel fellowship: presentation of graphical abstract
Chairs: E. Palma, UK; ECIC Chair

17:30 - 18:50 HÖRSAAL 3 (LECTURE HALL 3)
Management of alcohol-related liver disease (2)

Session 26: Alcohol-related liver disease: what is new?

Chairs: C. Moreno, BEL; C. Lackner, AUT

Strategies to identify in clinical practice alcohol-related liver disease patients before decompensated stage
E. Pose, ESP

How to define and manage patients with alcohol-related liver disease and metabolic syndrome?
A. Louvet, FRA

When to perform a liver biopsy in patients with alcohol-related liver disease?

R. Stauber, AUT

Severe alcohol-associated hepatitis: current management and future pipeline
P. Mathurin, FRA

17:30 - 18:50 HÖRSAAL 4 (LECTURE HALL 4)
Iron and alcohol-related liver disease

Session 31: Iron overload in alcohol use disorder - novel insights

Chairs: D. König-Castillo, AUT; S. Hametner, AUT

Enhanced red blood cell turnover is associated with alcoholic liver diseases and mortality
S. Müller, GER

Hepatocyte efferocytosis of red blood cells: a novel mechanism of liver iron overload in alcoholic liver disease
C. Zheng, GER

Neurodegeneration associated with iron accumulation in the human brain
S. Hametner, AUT

Brain iron overload and thiamine deficiency - a key pathway to explain and prevent cognitive decline in alcohol use disorder?
S. Listabarth, AUT

SUNDAY, SEPTEMBER 3RD

08:00 - 08:45 AULA

Plenary session 3: A novel treatment strategy for alcohol use disorder with phosphodiesterase 7 (PDE7) inhibitors

Chair: *M. Naassila, FRA*

R. Ciccocioppo, IT & USA

08:50 - 9:45 AULA

Nordman award lecture & ceremony

Chair: *M. Wojnar, POL*

S. Leclercq, BEL

10:00 - 10:40, AULA

General assembly

10:40 - 12:00 AULA

Alcohol-related inflammation and the brain

Session 32: Contribution of inflammatory mechanisms to alcohol-related brain abnormalities: a translational approach

Chairs: *P. de Timary, BEL; A. L. Pitel, FRA*

Exploring the role of x-binding protein-1 (XBP1) in the gut-brain axis during alcohol-related liver disease

C. Sanz-García, ESP

Investigating the evolution and the links between systemic inflammation, behavioral symptoms and brain structure during early alcohol cessation in alcohol use disorders

G. Petit, BEL

Progression of microstructural alterations in the brain during early alcohol abstinence: neurobiological substrates, inflammation and therapeutic targets

M. Selim, ESP

Different inflammatory pathways in severe alcohol use disorder

L. Lebedel, FRA

10:40 - 11:40 HÖRSAAL 3 (LECTURE HALL 3)

Alcohol and heart disease

Session 34: Alcohol-related heart disease

Chairs: *D. Scherr, AUT; P. Rainer, AUT*

Holiday heart: Alcohol-related atrial fibrillation

D. Scherr, AUT

Alcohol-related cardiomyopathy

E. Kolesnik, AUT

Cirrhotic cardiomyopathy (virtual)

S. Möller, DK

SUNDAY, SEPTEMBER 3RD

10:40 - 12:00 HÖRSAAL 4 (LECTURE HALL 4)

Session 36: Free oral presentations (2)

Chairs: *M. Wojnar, POL; E. Palma, UK*

Prenatal alcohol exposure impairs mouse somatosensory cortex development by delaying projection neurons migration

S. Laguesse, BEL

Targeting fibrosis in alcohol-related liver disease: unveiling the therapeutic impact of extracellular matrix remodelling by the cyclophilin inhibitor rencofilstat

U. Rastovic, UK

Chronic ethanol feeding exacerbates systemic dyslipemia and accelerates aortic lesion formation in LDLR-/- mice on Western diet

C. Hoebinger, AUT

Chronic pain as a risk factor to suffer alcohol use disorder: Alterations in astrocytes and microglia in the mesocorticolimbic system

P. Andres-Herrera, ESP

Effects of dietary glycine on metabolic steatohepatitis in diabetic KK-Ay mice through remodeling of hepatic lipid profile

A. Uchiyama, JPN

Observational and genetic associations of alcohol with risk of gout

I. P. Kei, UK

Targeting the gut barrier in alcohol-related liver disease: a focus on gut transcriptomics

E. M. Maxan, UK

Ethanol-induced alterations in the gut-liver axis promotes alcohol-associated liver disease:

Protection by betaine treatment

K. Khusum, USA

12:20 - 13:40 AULA

GABA_B Receptor and alcohol use disorder

Session 33: GABA_B receptor and alcohol use disorder: preclinical and clinical update

Chairs: *R. Agabio, IT; M. Naassila, FRA*

Sex-related difference in the efficacy of baclofen enantiomers on ethanol self-administration and dopamine transmission in rats

J. Jeanblanc, FRA

Suppressing effects of KK-92A, a novel positive allosteric modulator of the GABAB receptor, on alcohol drinking and self-administration in alcoholpreferring rats

G. Colombo, IT

Baclofen and alcohol use disorder: results from the latest cochrane metaanalysis

R. Agabio, IT

Baclofen in alcohol use disorder: data provided by the French “Temporary recommendation for use 2014-2017 cohort”

B. Rolland, FRA

SUNDAY, SEPTEMBER 3RD

12:20 - 14:00 HÖRSAAL 3 (LECTURE HALL 3)

Korsakow's syndrome update

Session 35: Intergrative approach to Korsakoff's syndrome: an old story revisited

Chair: A. L. Pitel, FRA

Going downhill? Differences between patients with "uncomplicated" alcohol use disorder, alcohol-related cognitive impairments, and Korsakoff's syndrome on cognitive and neuropsychiatric measures

Y. Rensen, NL

Distinct sleep alterations in alcohol use disorder patients with and without Korsakoff's syndrome

A. Laniece, FRA

Thiamine transport and genetics: recent evidences of increased biological vulnerability to alcohol related Wernicke-Korsakoff syndrome

I. Guerrini, UK

Looking beyond alcohol-related neurocognitive disorders: neuropsychological and brain specificities of Korsakoff's syndrome compared to Alzheimer's disease

C. Soussi, Caen, France

12:20 - 14:00 HÖRSAAL 4 (LECTURE HALL 4)

Intensive care

Session 37: Emergencies in alcohol-related disorders

Chair: L. Kramer, AUT; R. Stauber, AUT

Prevention and treatment of acute alcohol withdrawal

D. König-Castillo, AUT

Hyponatremia

W. Ribitsch, AUT

The trajectory of acute hepatic decompensation in ALD (virtual)

K. Stauffer, AUT

Management of ACLF in ALD

L. Kramer, AUT

14:00 - 14:30, AULA
Closing remarks & Fare well

SPEAKERS

Addolorato Giovanni - Rome, IT

Catholic University of Rome; Medical and Surgical Sciences

Agabio Roberta - Monserrato (CA), IT

University of Cagliari; Biomedical Sciences

Airagnes Guillaume - Paris, FRA

French Monitoring Center for Drugs and Drugs Addiction

Alho Hannu - Helsinki, FIN

University of Helsinki; Unit of Substance Abuse

Almeida-Antunes Natália - PRT

University of Minho; School of Psychology

Andre Judith - Amiens, FRA

Université de Picardie Jules Verne; UFR de Pharmacie

Andrés-Herrera Paula - Burjassot, ESP

University of Valencia; Pharmacy and Pharmaceutical Technology and Parasitology

Antón Toro Luis F. - Madrid, ESP

University Complutense of Madrid

Bansal Ruchi - Enschede, NL

University of Twente; Translational Liver Research

Barbier Estelle - Linköping, SWE

Linköping University

Baumann Anja - Vienna, AUT

University of Vienna; Department of Nutritional Sciences, Molecular Nutritional Science

Becchetti Chiara - Milano, IT

Niguarda Hospital, Hepatology

Bergheim Ina - Leonberg, AUT

University of Vienna, nutritional sciences

Billaux Pauline - Louvain-la-Neuve, BEL

UCLouvain; Psychological Sciences Research Institute

Caraceni Paolo - Bologna, IT

Alma Mater Studiorum University of Bologna

Carbia Carina - Louvain-la-Neuve, BEL

Université Catholique de Louvain - UCLouvain Louvain Experimental Psychopathology Research Group (UCLEP), Psychological Sciences Research Institute (IPSY)

Carrieri Patrizia - Marseille, FRA

Aix Marseille Université - Inserm; SESSTIM

Casanova Clémence - Marseille, FRA

Aix Marseille Université - Inserm

Casey Carol - Omaha, USA

University of Nebraska Medical Center; Internal Medicine

Chick Jonathan Dale - North Berwick, UK

Castle Craig Hospital; Psychiatry

Chokshi Shilpa - London, UK

The Foundation for Liver Research; Liver Immunology

Ciccocioppo Roberto - Camerino, IT

University of Camerino; School of Pharmacy

Claus Eric - Albuquerque, USA

The Mind Research Network

Coleman Leon - Chapel Hill, USA

UNC Chapel Hill School of Medicine; Pharmacology

Colombo Giancarlo - Monserrato (CA), IT

National Research Council of Italy; Neuroscience Institute

Cortez-Pinto Helena - Lisbon, PRT

Clinica-Universitaria-de-Gastroenterologia

Coulaud Pierre-Julien - Montreal, CA, USA

University of Montreal; Preventive and social medicine

Courtois Anoisia - Amiens, FRA

Université de Picardie Jules Verne; GRAP INSERM 1247

de Timary Philippe - Louvain, BEL

UCLouvain

Denk Helmut - Graz, AUT

Medical University of Graz, Institute of Pathology

Desmedt Olivier - Lausanne, CH

UNIL - Université de Lausanne

Dhanda Ashwin - Plymouth, UK

University of Plymouth; Faculty of Health

Domi Esi - Camerino, IT

University of Camerino; School of Pharmacy; Center for Neuroscience

Dousset Clémence - Uccle, BEL

Université Libre de Bruxelles; Psychology

Farzi Aitak - Graz, AUT

Medical University Graz; Division of Pharmacology

Fennel, R. - Hull, UK

Fickert Peter - Graz, AUT

Medical University Graz; Gastroenterology

Gautier Mado - Louvain-la-Neuve, BEL

UCLouvain

Gobejishvili Leila - Louisville, USA

University of Louisville; Physiology

Grgurevic Ivica - Zagreb, HRV

University Hospital Dubrava Zagreb; Department of

Gastroenterology, Hepatology and Clinical Nutrition

Guerrini Irene - London, UK

King's College London; Institute of Psychiatry,

Psychology & Neuroscience

Guiraud Julien - Amsterdam, NL

Amsterdam University Medical Centers; Department of Psychiatry

Hadjihambi Anna - Oxted, UK

The Roger Williams Institute of Hepatology

Hametner Simon - Vienna, AUT

Medical University of Vienna

Hamieh Nadine - Paris, FRA

Institut du Cerveau - Paris Brain Institute

Harada Takayuki - Tsukuba, JPN

University of Tsukuba; Faculty of Human Sciences

Heck Michelle - Liège, BEL

Université de Liège; Quantitative Psychology

Hoebinger Constanze - Vienna, AUT

Medical University of Vienna Austria; Department. of Laboratory Medicine

Hofer Benedikt S. - Vienna, AUT

Medical University of Vienna; Gastroenterology and Hepatology

Horvath Angela - Graz, AUT

Medical University of Graz; Gastroenterology and Hepatology

Ikejima Kinechi - Tokyo, JPN

Juntendo University School of Medicine

Im Pek Kei - Oxford, UK

University of Oxford

Jangard Simon - Stockholm, SWE

Karolinska Institutet; Department of Clinical Neuroscience

Jeanblanc Jérôme - Amiens FRA

Université de Picardie Jules Verne; INSERM U1247

SPEAKERS

Johnson Bankole - Miami, USA

Karkin University

Kaltenböck Alexander - Vienna, AUT

Medical University of Vienna

Kärkkäinen Olli - Kuopio, FIN

University of Eastern Finland; School of Pharmacy

Keshavarzian Ali - Chicago, IL, USA

Rush University Medical Center; Rush Center for

Integrated Microbiome & Chronobiology Research

Kharbanda Kusum - Omaha, USA

VA Medical Center/UNMC; Research Service R-151/Internal Medicine

Kolesnik Ewald - Graz, AUT

Medical University of Graz; Division of Cardiology

König-Castillo Daniel - Vienna, AUT

Medical University of Vienna, Vienna, Austria Clinical

Division of Social Psychiatry, Department of Psychiatry and Psychotherapy

Kramer Ludwig - Vienna, AUT

Hospital Hietzing; 1. Medical Institute

Kukla Michal - Cracow, POL

University Hospital Cracow; Department of Endoscopy

Kumar Lakshmi - Pittsburgh, USA

Carnegie Mellon University

Lackner Carolin - Graz, AUT

Medical University of Graz; Institute of Pathology

Laguesse Sophie - Liege, BEL

University of Liège (ULiège) GIGA-Neurosciences

Laniece Alice - Mont Saint Aigne, FRA

Université de Rouen-Normandie; Psychology

Lebedel Louise - Caen, FRA

Normandie Univ, UNICAEN, INSERM, U1237

Leclercq Sophie - Brussels, BEL

Université catholique de Louvain; Institute of Neuroscience

Lesch Otto-Michael - Breitenfurt, AUT

Medical University Vienna; Social Psychiatry

Listabarth Stephan - Vienna, AUT

Medical University of Vienna; Psychiatry

Logge Warren - Camperdown, AUS

Sydney Local Health District

Louvet Alexandre - Lille, FRA

Hôpital Huriez

Luo Jia, PhD - Iowa City, USA

The University of Iowa; Pathology

Machida Keigo, PhD - CA, USA

University of Southern California; Molecular Microbiology and Immunology

Maillard Angéline - Paris, FRA

Hôpital Fernand Widal APHP; Médecine Addictologique

Manning Lesley - Plymouth, UK

South West Liver Buddies

Mathurin Philippe - Lille, FRA

CHRU Lille; Service Maladies de l'Appareil Digestif

Matta Joane - Paris, FRA

INSERM

Maurage Pierre - Louvain-la-Neuve, BEL

Louvain Experimental Psychopathology research group (LEP), Psychological Science Research Institute, UCLouvain, Louvain-la-Neuve, Belgium; Psychological Science Research Institute

Maxan Maria-Emanuela - London, UK

King's College London

McNiven Mark - Rochester, USA

Mayo Clinic Rochester Gastroenterology Research

Meinhardt Marcus - Mannheim, GER

ZI-Mannheim; Psychopharmacology

Molina Patricia - New Orleans, USA

Louisiana State University Health Sciences Center New Orleans Physiology

Möller Søren - Copenhagen, DK

Hvidovre Hospital; Dept. Clinical Physiology and Nuclear Medicine

Moreno Christophe - Brussels, BEL

Hôpital universitaire de Bruxelles; Department of Gastroenterology, Hepatopancreatology and Digestive oncology

Morgan Marsha - London, UK

University College London; Institute for Liver & Digestive Health

Müller Sebastian - Heidelberg, GER

University of Heidelberg, Center for Alcohol Research

Naassila Mickaël - Amiens, FRA

Université de Picardie Jules Verne; UMR INSERM U1247

Nagy Laura - Cleveland, USA

Cleveland Clinic; Department of Inflammation and Immunology

Osna Natalia - Omaha, USA

University of Nebraska Medical Center; Internal Medicine/ Pharmacology and Experimental Neuroscience

Oettl Karl - Graz, AUT

Medical University of Graz; Division of Medicinal Chemistry

Pabst Arthur - Louvain-La-Neuve, BEL

UCLouvain IPSY, Faculty of psychology and educational sciences

Palma Elena - London, UK

The Roger Williams Institute of Hepatology;

The Foundation for Liver Research

Pandey Subhash C. - Chicago, USA

University of Illinois at Chicago & Center for Alcohol

Research in Epigenetics

Patel Vishal - UK

The Roger Williams Institute of Hepatology; The

Foundation for Liver Research; Microbiome in ACLD Research

Petitejean Mathieu - Princeton, NJ, USA

PharmaNest Inc.

Petit Geraldine - Louvain, BEL

UCLouvain; Institute of Neuroscience

Petrosyan Armen - Omaha, USA

University of Nebraska Medical Cent; Biochemistry and Molecular Biology

Pitel Anne Lise - Caen, FRA

Normandie Univ, UNICAEN, INSERM, U1237; Psychology

Popescu Alina - Timisoara, ROU

Victor Babes University of Medicine and pharmacy

Timisoara; Gastroenterology and Hepatology

Pose Elisa - Barcelona, ESP

Hospital Clinic de Barcelona

Preuss Ulrich - Ludwigsburg, GER

RKH Hospital Ludwigsburg Psychiatry, Psychotherapy,

Psychosomatic Medicine

Procopet Bogdan - Cluj-Napoca, ROU

Regional Institute of Gastroenterology and Hepatology

SPEAKERS

Puhakka Eemeli - Kuopio/Joensuu, FIN

University of Eastern Finland

Quertemont Etienne - Liège, BEL

Université de Liège; Psychology and Neuroscience of Cognition

Radwańska Katarzyna, PhD -

Warsaw, POL

Nencki Institute of Experimental Biology (PAS)

Rainer Peter - Graz, AUT

Medical University Graz; Division of Cardiology

Dragana Rajcic - Vienna, AUT

Medical University of Vienna; Basic Sciences

Rao Radhakrishna - Memphis, USA

*University of Tennessee Health Science Center
Physiology*

Rastovic Una - London, UK

The Foundation for Liver Research

Rensen Yvonne - Arnhem, NL

*Vincent van Gogh Korsakoff Centre for alcohol related
cognitive impairments*

Ribitsch Werner - Graz, AUT

LKH-Univ. Klinikum Graz; Department of Internal Medicine

Riva Antonio - London, UK

The Roger Williams Institute of Hepatology;

The Foundation for Liver Research

Roberto Marisa - La Jolla, USA

The Scripps Research Institute; Molecular Medicine Department

Rodrigues Susana - Bern, CH

Inselspital Universitätsspital Bern; UVCN, Hepatology

Rolland Benjamin - Bron, FRA

Hospices Civils de Lyon; Addiction Medicine

Romeo Stefano - Gothenburg & Catanzaro,

SWE & IT

*University Magna Graecia; Department of Medical &
Surgical Science*

Ronis Martin - New Orleans, USA

LSUHSC - New Orleans; Pharmacology

Sakellariou Stratigoula - Athens, GRC

Laiko General Hospital; 1st Dept of Pathology

Sanz-García Carlos - Madrid, ESP

Complutense Institute for International Studies, ICEI;

Complutense University of Madrid, UCM; Immunology

Scherr Daniel - Graz, AUT

Medical University of Graz; Division of Cardiology

Schwantes-An Tae-Hwi - Indiana, USA

*Indiana University School of Medicine; Department of
Medical and Molecular Genetics*

Secara Otilia - Livia - Fribourg, CH

Universitäre Psychiatrische Dienste Bern; Addictology

Selim Mohamed - Alicante, ESP

Instituto de Neurociencias

Seth Devanshi - Sydney, AUS

Edith Collins Centre; Sydney Local Health District

Shirasaka Tomohiro - Sapporo, JPN

Teine Keijinkai Medical Center; Department of Psychiatry

Soussi Célia - Caen, FRA

Laboratoire PHIND, Inserm 1237

Sporea Ioan - Timisoara, ROU

Victor Babes University of Medicine and Pharmacy

Timisoara; Gastroenterology and Hepatology

Prof. Dr. Stange Jan - Rostock, GER

University of Rostock; Division of Nephrology

Stärkel Peter - Bruxelles, BEL

Cliniques Universitaires Saint-Luc; Hepato-gastroenterology

Stauber Rudolf - Graz, AUT

Medical University of Graz; Department of Internal Medicine

Staufer Katharina - Vienna, AUT

Medical University of Vienna; Department of Surgery

Stefanescu Horia - Cluj-Napoca, ROU

Liver Unit; Regional Institute of Gastroenterology and

Hepatology

Suárez - Samuel - Ixelles, BEL

Université catholique de Louvain; Universidade de Santiago de

Compostela; Institut de Recherche en Sciences Psychologiques,

Louvain Experimental Psychopathology research group

Thiele Maja - Odense, DK

Odense University Hospital; Department of

Gastroenterology and Hepatology and OPEN

Tikhanovich Irina - Kansas City, USA

University of Kansas Medical Center; Internal Medicine,

Translational and Clinical Research Institute, Faculty of Medical

Sciences, Newcastle University, Newcastle upon Tyne

Tiniakos Dina - Athens, GRC

National and Kapodistrian University of Athens; Pathology

Topiwala Anya - London, UK

University of Oxford; Dep. of Psychiatry

Uchiyama Akira - Tokyo, JPN

Junendo University Graduate School of Medicine

Valenti Luca - Milano, IT

Università degli Studi di Milano; Department of

Pathophysiology and Transplantation

Van den Brink - Amsterdam, NL

Amsterdam University Medical Centers; Department of Psychiatry

Ventura Cots Meritxell - Barcelona, ESP

Hospital Universitari Vall d'Hebron

Verdejo-Garcia Antonio - Melbourne, AUS

Monash University; Turner Institute for Brain and Mental

Health

Wagner Martin - Graz, AUT

Medical University of Graz; Gastroenterology and

Hepatology

Wagner-Skacel Jolana - Graz, AUT

Medical University of Graz; Department of Medical

Psychology

Walter Henriette - Vienna, AUT

Medical University of Vienna; Department of Psychiatry

and Psychotherapy

Weber Sabine - Vienna, AT

Medical University of Vienna

Weiss Nicolas - London, UK

Université Sorbonne, Department of Neurology

Witkiewitz Katie - Cedar Crest, USA

University of New Mexico

Wojnar Marcin - Warsaw, POL

Medical University of Warsaw

Yamashina Shunhei - Tokyo, JPN

Junendo Nerima Hospital; Department of Gastroenterology

Zatloukal Kurt - Graz, AUT

Medical University Graz; Diagnostic and Research

Institute of Pathology

Zheng Chaowen - Heidelberg, GER

University of Heidelberg; Center for Alcohol Research



19th European Society for Biomedical Research on Alcoholism Conference

September 1st - September 3rd 2023
Medical University Graz



www.esbra2023.at